AXGN

SEC source: 0000805928-22-000127 · wf-form4_167114569833528.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,171

Underlying: Common Stock · 43,171 shares

Expires 2032-12-13

F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 13, 2023.

SEC source: 0000805928-22-000123 · wf-form4_166881200162320.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,698

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.18 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-22-000121 · wf-form4_166863270834343.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,583

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.51 to $13.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-22-000119 · wf-form4_166811453210822.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,583

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000805928-22-000107 · wf-form4_166026898857805.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 365,583

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-22-000105 · wf-form4_165999536701295.xml · nonDerivative · entry 2

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 374,469

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F3 · acquired: The reported price in Colum 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging for $10.15 to $10.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote,

SEC source: 0000805928-22-000105 · wf-form4_165999536701295.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,515

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.35 to $10.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-22-000098 · wf-form4_165888256034498.xml · derivative · entry 3

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,000 shares

Expires 2022-08-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-22-000098 · wf-form4_165888256034498.xml · nonDerivative · entry 2

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,515

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 83,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 52,704 shares of common stock.

SEC source: 0000805928-22-000098 · wf-form4_165888256034498.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,811

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 83,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 52,704 shares of common stock.

SEC source: 0000805928-22-000079 · wf-form4_165826091626398.xml · derivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Stock Option (right to purchase) · 59,395 shares

Expires 2023-07-11

F1 · derivative.exercise_date: 1. Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on July 11, 2023.

SEC source: 0000805928-22-000096 · wf-form4_165834762985277.xml · nonDerivative · entry 2

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,081

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000094 · wf-form4_165834747880252.xml · nonDerivative · entry 2

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,094

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000092 · wf-form4_165834728313660.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,752

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000090 · wf-form4_165834712363395.xml · nonDerivative · entry 2

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,242

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000088 · wf-form4_165834694953675.xml · nonDerivative · entry 2

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,855

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000086 · wf-form4_165834680588166.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 981,549

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000084 · wf-form4_165834665653448.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,347

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000082 · wf-form4_165834646661072.xml · nonDerivative · entry 2

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,197

F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022.

SEC source: 0000805928-22-000096 · wf-form4_165834762985277.xml · nonDerivative · entry 1

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,206

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000094 · wf-form4_165834747880252.xml · nonDerivative · entry 1

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,751

F1 · shares: This reflects the number of shares that vested on July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000092 · wf-form4_165834728313660.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,157

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000090 · wf-form4_165834712363395.xml · nonDerivative · entry 1

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,340

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000088 · wf-form4_165834694953675.xml · nonDerivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,512

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000086 · wf-form4_165834680588166.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 988,409

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000084 · wf-form4_165834665653448.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,294

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000082 · wf-form4_165834646661072.xml · nonDerivative · entry 1

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,854

F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · derivative · entry 4

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · derivative · entry 3

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · derivative · entry 4

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · derivative · entry 3

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · derivative · entry 2

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000069 · wf-form4_165428734992822.xml · nonDerivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,036

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-22-000066 · wf-form4_165428708809863.xml · derivative · entry 3

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,500

Underlying: Common Stock · 15,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000066 · wf-form4_165428708809863.xml · nonDerivative · entry 2

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,798

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000066 · wf-form4_165428708809863.xml · nonDerivative · entry 1

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-22-000067 · wf-form4_165428722800361.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000067 · wf-form4_165428722800361.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · derivative · entry 4

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · derivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000065 · wf-form4_165428697291546.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · derivative · entry 4

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · derivative · entry 3

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · derivative · entry 2

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · nonDerivative · entry 1

NEELS GUIDO J · CIK 0001222362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · derivative · entry 4

Gold Mark Stephen · CIK 0001531332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F5 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · derivative · entry 3

Gold Mark Stephen · CIK 0001531332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F5 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.